Pacira BioSciences, Inc. (PCRX)

Pretax margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	-63,106	-54,912	100,545	101,815	61,701	9,913	-4,619	-20,466	13,302	25,173	47,335	50,976	56,406	75,296	57,215	24,256	20,089	3,855	-8,111	327
Revenue (ttm)	US$ in thousands	700,966	694,957	690,310	681,754	674,978	665,689	669,229	669,173	666,823	654,062	614,318	580,497	541,533	510,887	500,649	440,564	427,221	421,097	408,298	435,397
Pretax margin		-9.00%	-7.90%	14.57%	14.93%	9.14%	1.49%	-0.69%	-3.06%	1.99%	3.85%	7.71%	8.78%	10.42%	14.74%	11.43%	5.51%	4.70%	0.92%	-1.99%	0.08%

December 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-63,106K ÷ $700,966K
= -9.00%

Pacira BioSciences, Inc.'s pretax margin fluctuated over the period from March 31, 2020, to December 31, 2024. The pretax margin represents the company's profitability before accounting for taxes and is a key indicator of its operational efficiency.

The pretax margin ranged from -9.00% to 14.93% during this period, showing significant variability in the company's ability to generate profits from its operations. The highest pretax margin was observed on March 31, 2024, at 14.93%, indicating strong profitability during that quarter.

However, there were also periods when the company experienced negative pretax margins, particularly in the second half of 2024, with values of -7.90% and -9.00% on September 30, 2024, and December 31, 2024, respectively. These negative margins suggest that the company's expenses and costs may have outpaced its revenue during those quarters.

Overall, Pacira BioSciences, Inc.'s pretax margin trended upwards from March 31, 2020, to March 31, 2024, with some fluctuations along the way. Analyzing the reasons behind these fluctuations could provide insights into the company's operational performance and efficiency in managing its costs and expenses.